CONTIPHARMA

CONTIPHARMA has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. For CONTIPHARMA, one filing cycle of the annual accounts is missing. The 2024 annual accounts show equity of €2.2m and a net result of -€151,785. Equity is shrinking by about 3.3% per year across the filed financial years. Its solvency ranks better than 36% of 6,069 sector peers (NACE 46, financial year 2024). The company has been active since 1999 and the Belgian Official Gazette contains no insolvency or warning signals.